Research collaborations by multi-national research oriented pharmaceutical firms: 1988-1997

R and D Management

Volumn 29, Issue 3, 1999, Pages 219-231

  Tapon, Francis ^a   Thong, Mona ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033437688     PISSN: 00336807     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9310.00132     Document Type: Article

References (35)

1. Aley, J. (1996) Give it away and get rich! Fortune, 139, 11, 10 June, 90-98.
2. Arthur, W.B. (1996) Increasing returns and the new world of business. Harvard Business Review, 74, 4, July-August, 100-109.
3. Barney, J.B. and Hansen, M.H. (1994) Trustworthiness as a source of competitive advantage. Strategic Management Journal, 15, special issue, Winter, 175-190.
4. Business Week (1995a) Procter and Gamble heads for the medicine cabinet. 17 August, 28.
5. Business Week (1995b) The case against mergers. 30 October, 122-138.
6. Business Week (1997) Can Honda build a world car? 8 September, 100-108.
7. Collis, D.J. (1994) How valuable are organizational capabilities? Strategic Management Journal, 15, special issue, Winter, 143-152.
8. della Valle, A. and Gambardella, A. (1993) 'Biological' revolution and strategies for innovation in pharmaceutical companies. R&D Management, 23, 4, 287-302.
9. Doz, Y.L. (1996) The evolution of cooperation in strategic alliances: initial conditions or learning processes? Strategic Management Journal, 17, special issue, Summer, 55-83.
10. The Economist (1995) Unseemly couplings. 335, 7914, 13 May, 66-69.
11. The Economist (1997) Instant coffee as management theory. 342, 8001, 25 January, 57.
12. Gambardella, A. (1992) Competitive advantages from inhouse scientific research: the U.S. pharmaceutical industry in the 1980s. Research Policy, 21, 9, 391-407.
13. Hamel, G. and Prahalad, C.K. (1989) Strategic intent. Harvard Business Review, May-June, 63-76.
14. Henderson, R. and Cockburn, I. (1996) Scale, scope and spillovers: the determinants of research productivity in drug discovery. Rand Journal of Economics, 27, 1, Spring, 32-59.
15. Hilmer, F. and Donaldson, L. (1996) Management Redeemed: Debunking the Fads that Undermine our Corporations. Free Press.
16. Kreiner, K. and Schultz, M. (1990) Crossing the institutional divide: networking in biotechnology. Paper presented at the Tenth Annual International Strategic Management Society Conference, Stockholm, Sweden, September.
17. Lacity, M.C., Willcocks, L.P. and Feeny, D.F. (1995) IT outsourcing: maximize flexibility and control. Harvard Business Review, 73, 3, May-June, 84-93.
18. Leonard-Barton, D. (1992) Core capabilities and core rigidities: a paradox in managing new product development. Strategic Management Journal, Special Summer Issue, 13, 111-126.
19. MacMillan, I.C. and McGrath, R.G. (1997) Letter to the editor in response to M.E. Porter's article, 'What is strategy?' Harvard Business Review, 75, 1, January-February, 154-156.
20. Moore, J. (1996) The Death of Competition: Leadership and Strategy in the Age of Business Ecosystems. Harper Collins. Adapted in 'The death of competition', Fortune, 133, 7, 15 April, 1996, 142-144.
21. Moore, J. (1996) The Death of Competition: Leadership and Strategy in the Age of Business Ecosystems. Harper Collins. Adapted in 'The death of competition', Fortune, 133, 7, 15 April, 1996, 142-144.
22. Pharmaceutical Research and Manufacturers of America (PhRMA, 1998). Http://www.pharma.org/
23. Pisano, G.P., Shan, W. and Teece, D.J. (1988) Joint ventures and collaboration in the biotechnology industry. In Mowery, D.C. (ed.), International Collaborative Ventures in U.S. Manufacturing. American Enterprise Institute/ Ballinger Publications, pp. 183-222.
24. Pisano, G.P. (1991) The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry. Research Policy, 20, 237-249.
25. Porter, M.E. (1996) What is strategy? Harvard Business Review, 74, 6, November-December, 61-78.
26. Quinn, J.B., Anderson, P. and Finkelstein, S. (1996) Making the most of the best. Harvard Business Review, 74, 2, March-April, 71-80.
27. Recombinant Capital (ReCap) (1998). Http://www.recap.com/
28. Ring, P.S. and Van De Ven, A.H. (1992) Structuring cooperative relationships between organizations. Strategic Management Journal, 33, 7, October, 483-498.
29. Stipp, D. (1997) The real biotech revolution. Fortune, 135, 6, 31 March, 56-73.
30. Tapon, F. (1989) A transaction costs analysis of innovations in the organization of pharmaceutical R&D. Journal of Economic Behavior and Organization, 12, 197-213.
31. Tapon, F. and Cadsby, C.B. (1996) The optimal organization of research: evidence from eight case studies of pharmaceutical firms. Journal of Economic Behavior and Organization, 31, 381-399.
32. Tyler, B.B. and Steensma, H.K. (1995) Evaluating technology collaborative opportunities: a cognitive modeling perspective. Strategic Management Journal, special issue, Summer, 16, 43-70.
33. Whittaker, E. and Bower, D.J. (1994) A shift to external alliances for product development in the pharmaceutical industry. R&D Management, 24, 3, July, 249-260.
34. Williamson, O.E. (1975) Markets and Hierarchies. New York: Free Press.
35. Williamson, O.E. (1985) The Economic Institutions of Capitalism. New York: Free Press.